Original-Research: VOQUZ Labs AG (von NuWays AG): Kaufen
Original-Research: VOQUZ Labs AG - from NuWays AG
Classification of NuWays AG to VOQUZ Labs AG
Company Name: VOQUZ Labs AG
ISIN: DE000A3CSTW4
Reason for the research: Update
Recommendation: Kaufen
from: 10.04.2024
Target price: EUR 22.00
Target price on sight of: 12 Monaten
Last rating change:
Analyst: Philipp Sennewald
Strong momentum as S/4HANA effect should become visible
We hosted a digital roadshow with VOQUZ Labs CEO Martin Kögel, which provided valuable insights into the investment case. Here are the takeaways:
Current trading remains on a strong level after we already saw a pick-up in demand in H2 ’23 (+14% sales vs +3% in H1) as Mr. Kögel confirmed the company’s growth ambitions (10-20% yoy in ‘24e). The latter looks set to be mainly driven by further key account wins for the company’s flagship solution samQ, but also an improved contribution from visoryQ and remQ, which should be supported by the recently announced partnership with PwC (see our latest update).
visoryQ to drive growth and margins. The self-developed solution was first launched in Q4 ’22 and already contributed c. € 0.5m sales in FY ’23 (eNuW). Mind you, visoryQ is an SAP-ERP business case builder, providing in-depth scenario analyses for clients in order to optimize TCO. Especially when it comes to the S/4HANA transformation, it offers valuable decision support regarding the optimal strategy and should hence be in brisk demand of yet to migrate customers given the economic significance of the conversion. As the transformation is seen to accelerate in the coming quarters, VOQUZ looks set to be a main beneficiary, as we expect visoryQ sales to develop dynamically at a 65% CAGR ‘23p-26e.
M&A: With the acquisition of remedyne in 2023, VOQUZ tipped off its pursued buy and build strategy, which it intends to continue in 2024, as Management is already screening the market for possible targets. VOQUZ is seen to target companies in the SAP add-on space in order to facilitate cross-selling potential. Moreover, acquired solutions should be internationally applicable without any specific industry focus industry focus. While smaller targets like remedyne (€ 0.3m acquisition volume) could be financed out of the CFO, CEO Kögel intended that the company would likely need to tap the capital market in order to perform a larger acquisition.
Considering the excellent growth prospects of the company as well as the high scalability of the business model, the stock looks undervalued trading on a mere 1.2x EV/Sales and 8.0x EV/EBITDA ‘24e (0.9x/ 4.5x based on FY25e) while providing attractive returns on the other hand.
We hence reiterate BUY with an unchanged PT of € 22.00 based on DCF.
You can download the research here:
http://www.more-ir.de/d/29373.pdf
For additional information visit our website
www.nuways-ag.com/research.
Contact for questions
NuWays AG - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse.
++++++++++
-------------------transmitted by EQS Group AG.-------------------
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
The most important financial data at a glance | ||||||||
2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
Sales1 | 1,56 | 2,01 | 2,96 | 3,89 | 4,72 | 5,26 | 6,05 | |
EBITDA1,2 | 0,13 | 0,09 | 0,66 | 0,96 | 0,62 | 0,49 | 1,10 | |
EBITDA-Margin3 | 8,33 | 4,48 | 22,30 | 24,68 | 13,14 | 9,32 | 18,18 | |
EBIT1,4 | 0,03 | 0,24 | 0,45 | 0,62 | 0,26 | 0,04 | 0,00 | |
EBIT-Margin5 | 1,92 | 11,94 | 15,20 | 15,94 | 5,51 | 0,76 | 0,00 | |
Net Profit (Loss)1 | -0,02 | 0,29 | 0,44 | 0,48 | 0,06 | -0,08 | 0,00 | |
Net-Margin6 | -1,28 | 14,43 | 14,87 | 12,34 | 1,27 | -1,52 | 0,00 | |
Cashflow1,7 | -0,07 | 0,35 | 0,40 | 0,58 | 0,08 | -0,04 | 0,00 | |
Earnings per share8 | 0,00 | 0,28 | 0,42 | 0,46 | 0,06 | -0,07 | 0,30 | |
Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: Menold Bezler
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
INVESTOR-INFORMATION | ||||||
©boersengefluester.de | ||||||
VOQUZ Labs | ||||||
WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
A3CSTW | DE000A3CSTW4 | AG | 7,77 Mio € | 28.07.2021 | 9F4MG83M+WF |
PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
15,74 | 18,86 | 0,64 | 30,58 | 4,03 | -194,25 | 1,48 |
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
0,00 | 0,00 | 0,00 | 0,00% |
Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
02.07.2024 | 27.09.2024 | 23.05.2024 |
Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
-3,92% | -19,15% | +48,00% | +48,00% | -81,50% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.